Sirna compositions and methods targeting microtubule associated protein tau nucleic acids

MYPI2025001880A0Undetermined Publication Date: 2024-03-29ATALANTA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001880
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-29
Filing Date
2023-09-28
Publication Date
2024-03-29

Smart Images

  • Figure PI2025001880_DRAWING_001
    Figure PI2025001880_DRAWING_001
  • Figure PI2025001880_DRAWING_002
    Figure PI2025001880_DRAWING_002
  • Figure PI2025001880_DRAWING_003
    Figure PI2025001880_DRAWING_003
Patent Text Reader

Abstract

The instant application is directed to single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a microtubule-associated protein tau (MAPI) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5' phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a tauopathy. Fig. 1A
Need to check novelty before this filing date? Find Prior Art